GSA Capital Partners LLP Acquires Shares of 1,005,709 Humacyte, Inc. $HUMA

GSA Capital Partners LLP bought a new stake in Humacyte, Inc. (NASDAQ:HUMA) in the second quarter, Holdings Channel reports. The institutional investor bought 1,005,709 shares of the company’s stock, valued at approximately $785,000.

Several other hedge funds have also made changes to their positions in HUMA. Prudential Financial Inc. purchased a new position in shares of Humacyte during the second quarter worth about $28,000. Price T Rowe Associates Inc. MD raised its stake in Humacyte by 21.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock valued at $73,000 after acquiring an additional 13,175 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Humacyte by 41.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock valued at $96,000 after acquiring an additional 13,407 shares during the last quarter. Financial Advisors Network Inc. acquired a new stake in Humacyte during the 2nd quarter worth approximately $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Humacyte by 25.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,975 shares of the company’s stock worth $161,000 after acquiring an additional 15,649 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Price Performance

HUMA stock opened at $0.73 on Thursday. The stock’s fifty day simple moving average is $0.73 and its 200-day simple moving average is $0.89. The company has a quick ratio of 5.74, a current ratio of 6.21 and a debt-to-equity ratio of 2.07. Humacyte, Inc. has a 52-week low of $0.53 and a 52-week high of $2.55. The stock has a market capitalization of $198.16 million, a price-to-earnings ratio of -1.50 and a beta of 2.53.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). The firm had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. Equities research analysts expect that Humacyte, Inc. will post -0.4 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. TD Cowen dropped their target price on Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a report on Wednesday, June 17th. HC Wainwright increased their price target on Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Benchmark dropped their price objective on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a research note on Thursday, August 13th. Finally, BTIG Research restated a “buy” rating and set a $2.00 price objective on shares of Humacyte in a research report on Wednesday, August 12th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.11.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.